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Surveillance for drug-resistant parasites in human blood is a major
effort in malaria control. Here we report contrasting antifolate
resistance polymorphisms in Plasmodium falciparum when para-
sites in human blood were compared with parasites in Anopheles
vector mosquitoes from sleeping huts in rural Zambia. DNA encod-
ing P. falciparum dihydrofolate reductase (EC 1.5.1.3) was amplified
by PCR with allele-specific restriction enzyme digestions. Markedly
prevalent pyrimethamine-resistant mutants were evident in hu-
man P. falciparum infections—S108N (>90%), with N51I, C59R,
and 108N+51I+59R triple mutants (30–80%). This resistance level
may be from selection pressure due to decades of sulfadoxine/py-
rimethamine use in the region. In contrast, cycloguanil-resistant
mutants were detected in very low frequency in parasites from
human blood samples—S108T (13%), with A16V and 108T+16V
double mutants (∼4%). Surprisingly, pyrimethamine-resistant
mutants were of very low prevalence (2–12%) in the midguts of
Anopheles arabiensis vector mosquitoes, but cycloguanil-resistant
mutants were highly prevalent—S108T (90%), with A16V and the
108T+16V double mutant (49–57%). Structural analysis of the dihy-
drofolate reductase by in silico modeling revealed a key difference
in the enzyme within the NADPH binding pocket, predicting the
S108N enzyme to have reduced stability but the S108T enzyme to
have increased stability. We conclude that P. falciparum can bear
highly host-specific drug-resistant polymorphisms, most likely re-
flecting different selective pressures found in humans and mosqui-
toes. Thus, it may be useful to sample both human and mosquito
vector infections to accurately ascertain the epidemiological status
of drug-resistant alleles.
Emergence of drug-resistant Plasmodium falciparum continuesto pose a key obstacle to malaria control and elimination
efforts (1, 2). It is widely recognized that P. falciparum has a
daunting potential for developing resistance to any drug upon
wider introduction, including the new combination regimens with
or without artemisinin (3–7). Effective public health strategies
for surveillance and containment of resistance are therefore
paramount, and the World Health Organization has urged that
drug efficacy be closely monitored (8).
An instrumental approach widely adopted to help control
programs detect and thwart drug resistance is the molecular
surveillance of drug resistance-conferring P. falciparum mutants.
These molecular markers for resistance are best characterized
for chloroquine (9) and antifolate drugs (10–12). Antifolates are
extensively used across endemic countries in intermittent pre-
ventive therapy programs for malaria in pregnant women and in
children (13, 14). Antifolates are also constituents of artemisinin
combination therapy (ACT) regimens, such as proguanil–ato-
vaquone–artesunate and artesunate–sulfadoxine/pyrimethamine.
Antifolate resistance by P. falciparum malaria is well recog-
nized (15). Pyrimethamine resistance was first reported in rural
Tanzania >50 y ago (16), suggesting the existence of populations
of mutant organisms in the endemic region rather than rapid
appearance of new mutations. Discovery of pyrimethamine-
resistant mutations in parasite DNA encoding dihydrofolate
reductase (DHFR) implicated amino acid substitutions at key
residues—S108N, N51I, and C59R, as well as double or triple
mutants (15, 17–19). Cycloguanil, the active metabolite of pro-
guanil, is known to induce a different set of mutations in the gene
encoding parasite DHFR—S108T and A16V, as well as the
double mutant (15, 20, 21). During emergence of resistance, the
mutation at DHFR amino acid codon 108 is known to arise (22),
followed by mutations at the other positions in a stepwise course
accompanied by increasing levels of resistance in the multiple
mutants (11).
A combination of mutations S108N and I164L confers cross-
resistance to pyrimethamine and cycloguanil, which is height-
ened when the C59R or N51I is also present. A parallel array
of mutations in the P. falciparum dihydropteroate synthetase
(DHPS) gene at codons 436, 437, 540, and 581 similarly confers
resistance to DHPS inhibitors. Tracking such mutations has
proved valuable for monitoring the emergence of antifolate drug
resistance, as has been a corresponding chloroquine-resistant
marker in the P. falciparum chloroquine-resistant transporter
(Pfcrt) gene (23).
Current monitoring for P. falciparum drug-resistant alleles is
mostly based on genotyping malaria infections in humans found
positive by microscopic analysis of their blood. Infections in
vector mosquitoes are rarely considered, despite the insects be-
ing the definitive host where parasite genetic recombination
occurs. With evident field association between mosquito control
and drug-resistant P. falciparum prevalence in humans (24, 25),
we hypothesized that mosquitoes may play a role in influencing
drug-resistant allele epidemiology. To better define the existence
of drug-resistant alleles in native populations, we undertook
genomic phenotyping of P. falciparum DNA in parasites from
both humans and vector mosquitoes in an endemic region of
southern Zambia.
Results
Our study of malaria in southern Zambia involved visits to rural
households, where peripheral blood was drawn from the resi-
dents by finger prick and pyrethrum insecticide spray catches
were performed in their sleeping rooms. The region in Choma
District surrounding the settlement of Macha was known to ex-
hibit seasonal malaria with thousands of cases of clinical malaria
seen at the regional hospital. Sulfadoxine/pyrimethamine had
been used in the area for decades. Insecticide-treated bed nets
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had been introduced 3 y earlier, as had ACT. A severe drought
had occurred the previous year.
After giving informed consent, 2,779 human subjects were
studied. The individuals ranged from 2 wk to 96 y of age, median
age 12 y. Peripheral blood samples from all were examined by
microscopy the same day. Only 169 individuals tested positive for
malaria parasites (referred to as “blood smear-positive”). Most
had low-grade asexual parasitemia, ranging from 38 to 245,000
parasites per microliter (geometric mean parasite density, 1,478;
95% CI, 1,060–2,061 parasites per microliter). Of these, 23
(14%) were pyrexic with axillary temperatures of ≥37.5 °C. Of
the 2,610 individuals that tested negative by microscopy (referred
to as “blood smear-negative”), 65 (2.5%) were pyrexic.
Insecticide spray catches yielded 796 malaria vector mosqui-
toes from human sleeping rooms. Nearly all (99%) were
Anopheles arabiensis, and the remainder (1%) were Anopheles
funestus. The mosquitoes were examined microscopically and
individually dissected to separate the abdomen from the head and
thorax section. Eighty-one (10%) were positive for P. falciparum
in midguts and 64 (8%) in salivary glands, with only 4 (0.5%)
infected in both body sections.
DHFR Mutant Parasites in Human Blood. Because pyrimethamine
had been used in the region for decades, resistance poly-
morphisms were expected in the P. falciparum gene encoding
DHFR. From the 169 blood smear-positive individuals, a ran-
dom subset of samples from 86 was PCR amplified. Genotypes
for antifolate-resistant mutations (26) were obtained at one or
more loci from all 86. From the 2,610 blood smear-negative
individuals, a random subset of 475 samples was screened for
submicroscopic parasitemia by the same nested PCR for de-
tection of P. falciparum antifolate-resistant polymorphisms (26).
Only 93 were PCR-positive, and 88 of these were successfully
genotyped for antifolate-resistant mutations at one or more loci,
whereas the other 5 had amplicon products too faint for analysis
of restriction enzyme digestions (26). High levels of pyrimeth-
amine-resistant mutations were observed in each group (Fig. 1
and Table 1). The sentinel mutation, S108N, was practically
saturated (>90%). The other mutants, N51I, C59R, and the
108N+51I+59R triple mutant, were also prevalent (30–80%).
Cycloguanil-resistant mutants were not expected because the
progenitor molecule, proguanil, had not been routinely used in
the region or adopted for the Zambian national malaria control
program, despite clinical trials of the proguanil–atovaquone
regimen (27). The sentinel cycloguanil-resistant mutant S108T
was not detected in samples from blood smear-positive individ-
uals (Fig. 1 and Table 1), but samples from blood smear-negative
individuals revealed S108T, in a modest number (13%). The
second mutant, A16V, and the S108T+A16V double mutants
were not detected in samples from the blood smear-positive
individuals, but they were found in a small percentage of samples
(∼4%) from blood smear-negative individuals.
Because they were predominantly asymptomatic, 145 (83%) of
the 174 individuals whose samples were genotyped were unaware
of having taken antimalarials. Ten (6%) of the others had taken
sulfadoxine/pyrimethamine within the past 2 mo. Proportions of
pyrimethamine-resistant mutants were slightly higher in samples
from these individuals, albeit not statistically significant, possibly
due to the limited numbers. None of the individuals whose
samples were typed had previously taken trimethoprim/sulfa-
methoxazole (Cotrimoxazole or Septrin).
DHFR Mutant Parasites in Vector Mosquitoes. Despite high preva-
lence of mutant parasites in humans, prevalence of pyrimeth-
amine-resistant mutant parasites was substantially diminished in
midguts of Anopheles vector mosquitoes (Fig. 2 and Table1).
This result was unexpected, because the mosquitoes had ac-
quired parasites from humans as recently as 10 d previously. The
likelihood of finding these mutants had dropped 100-fold in the
mosquito phase; these differences were highly significant statis-
tically (Table 2). Although parasites containing pyrimethamine-
resistant mutations were least common in midguts, the sentinel
mutation, S108N, was relatively more prevalent in salivary glands
(>40%) than the other mutations (Fig. 2 and Table 1).
Surprisingly high levels of cycloguanil-resistant mutants were
observed in vector mosquitoes, especially in midgut samples (Fig.
2 and Table 1). Mosquito infections exhibited high prevalence of
cycloguanil-resistant S108T, A16V, and the 108T+16V double
mutant, which are currently believed to be rare or absent in
natural P. falciparum infections of Africa and elsewhere (28).
One midgut infection carried the I164L residue, which, as a
multiple mutant with S108N, C59R, and/or N51I, confers high
levels of resistance to both pyrimethamine and cycloguanil.
Another midgut infection bore a unique I164R residue that has
not been previously described for this locus. The composition of
antifolate-resistant mutants in mosquito infections was in-
dependent of feeding status (Table 3).
DNA Sequence Confirmations. Genotypes were confirmed by DNA
sequencing. Amplicons from M3-F/ and F-M4 primers (26) were
analyzed from subsets of human samples (six) and vector mos-
quito midgut (seven) and salivary gland samples (six). Poly-
morphisms in the gene encoding P. falciparum DHFR, as
determined by PCR and allele-specific restriction enzyme
digestions (Figs. 1 and 2 and Table 1), were confirmed by the
DNA sequencing. The sequences flanking the sentinel mutation
site at amino acid codon 108 are shown (Fig. 3).
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Fig. 1. Prevalence of P. falciparum pyrimethamine- and cycloguanil-re-
sistant DHFR mutants in human blood. Finger-prick samples were obtained
from humans with microscopic parasitemia (blood film-positive; n = 86; A)
and submicroscopic parasitemia (blood film-negative; n = 88; B). DNA was
PCR amplified and analyzed for allele-specific polymorphisms by restriction
digestion. y-axis numerals denote DHFR codons. Represented are WT, pyri-
methamine-resistant mutants (S108N, N51I, C59R, and triple mutants),
cycloguanil-resistant mutants (S108T, A16V, and double mutant), and mixed
alleles (WT+S108T or S108N+S108T).











Structural Alterations of DHFR in Resistance Mutants. Atomic
structures of P. falciparum DHFR illustrate the role of Ser-108 in
the function of the wild-type (WT) enzyme and the consequences
of S108N mutation [Protein Data Bank (PDB) ID codes 1J3I
and 3JSU]. Essential for nucleotide biogenesis in all organisms,
DHFR catalyzes reduction of dihydrofolate to tetrahydrofolate
with oxidation of NADPH to NADP+.
Modeling with the WT structure as the template revealed
major structural differences in the mutant enzymes. The binding
pocket for NADPH within the WT DHFR contains an important
2.56-Å hydrogen bond linking the side chain of Ser-108 to the
pyrophosphate moiety of NADPH (Fig. 4A Left). In contrast, the
sentinel pyrimethamine-resistant mutant S108N projects a side
chain that cannot form an effective hydrogen bond, because at
5.40 Å, the distance is too great (Fig. 4A Center). Similar to the
WT enzyme, the cycloguanil mutant S108T maintains the 2.56-Å
hydrogen bond with NADPH (Fig. 4A Right). The extra methyl
group in S108T does not cause any steric collisions but forms
van der Waals interactions with a nearby hydrophobic domain
composed of Met-104, Ile-112, and Ile-164 (Fig. 4B Right).
Discussion
Our studies revealed contrasting drug-resistant polymorphisms
in the P. falciparum gene encoding DHFR. The parasites in
human blood demonstrated high levels of pyrimethamine-re-
sistant mutants, whereas parasites in Anopheles vector mosqui-
toes exhibited high levels of cycloguanil-resistant mutants. This
surprising contrast raises several questions. Are we using optimal
allele detection methods? What is the role of antifolate drug
resistance in the mosquito phase of malaria? What is the func-
tional significance of the structural alterations of parasite DHFR?
Are contrasting drug-resistant polymorphisms unique to a single
malaria-endemic region, or is this a general phenomenon?
Our studies indicate that genotyping human blood smear-pos-
itive samples alone may underestimate the true profile of drug-
resistant alleles. Furthermore, although cycloguanil-resistant
mutants are currently believed to be rare or absent in natural P.
falciparum infections in Africa (28–30), they were found to exist at
high prevalence in the vector population. These mutants, S108T,
A16V, and the double mutant S108T+A16V, are prevalent in
parasites in mosquitoes, even though they are undetected by
current surveillance based on typing human blood smear-positive
samples. Rarer alleles, including I164L, and a unique allele,
I164R, were also observed in vectormosquitoes.Mosquitomidgut
infections with P. falciparum were acquired from the human
population within the previous 10 d, indicating that cycloguanil-
resistant alleles were present in human parasitemia. Detection of
low levels of S108T andA16V in samples from humans with blood
smear-negative infections confirmed this hypothesis. It is likely
that minority alleles in blood smear-positive infections escaped
detection due to selective amplification of the dominant alleles
during PCR. In Malawi, for example, presence of the rare I164L
mutant was recently documented in human P. falciparum infec-
tions by using a heteroduplex tracking assay (30), but the allele was
then subsequently detected in Kenya at low levels by regular PCR
(31). Inclusion of human submicroscopic parasitemia and vector
infections in epidemiological sampling may therefore facilitate
effective tracking and curtailment of resistant alleles before they
become public health problems. Although the possibility of de
novo origins for mutants cannot be ruled out (32), this expanded
sampling approach would remain useful.
Table 1. Determinations of P. falciparum DHFR resistant polymorphisms for parasites from
blood smear-positive and -negative humans and from vector mosquito midguts and salivary
glands
Infection S108N N51I C59R S108N+N51I+C59R A16V I164L 108T+16V
Human blood smear-positive
Mut 67 60 37 36 0 0 0
S108T 0 0 0 N/A 0 0 0
Mut + S108T 0 0 0 N/A 0 0 0
WT + mut 11 6 11 N/A 0 0 0
WT 6 15 34 43 84 74 84
Total 84 81 82 79 84 74 84
Human blood smear-negative
Mut 43 33 29 10 2 0 2
S108T 5 0 0 N/A 0 0 0
Mut + S108T 2 0 0 N/A 0 0 0
WT + mut 0 0 0 N/A 0 0 0
WT 2 11 18 22 44 39 44
Total 52 44 47 32 46 39 46
Mosquito midgut
Mut 7 6 1 1 38 1* 33
S108T 71 0 0 N/A 0 0 0
Mut + S108T 2 0 0 N/A 0 0 0
WT + mut 0 0 0 N/A 0 1 0
WT 1 43 62 40 29 44 34
Total 81 49 63 41 67 46 67
Mosquito salivary gland
Mut 27 7 11 4 2 0 1
S108T 26 0 0 N/A 0 0 0
Mut + S108T 0 0 0 N/A 0 0 0
WT + mut 1 0 0 N/A 0 0 0
WT 8 46 43 46 40 42 41
Total 62 53 54 50 42 42 42
Human blood smear-positive, n = 86; human blood smear-negative, n = 88; mosquito midgut, n = 81; mosquito
salivary gland, n = 64. N/A, not applicable.
*Midgut, I164R.
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Our results point to a pivotal role of mosquitoes in the epide-
miology of drug-resistant P. falciparum. Apart from harboring
minority alleles subpatent in humans, An. arabiensis clearly exer-
ted a dramatic depletion (as much as 100-fold) on P. falciparum
pyrimethamine-resistant alleles, despite prevailing sulfadoxine/
pyrimethamine drug pressure in the area. This mosquito selection
phenomenon on P. falciparum polymorphisms is distinct from
Kublin’s in vivo fitness burden in humans (33) and was evidently
independent and opposing to existing drug selection.
We speculate that vector-selective constraints on parasite-re-
sistant polymorphisms may reflect field links between mosquito
control and suppression of P. falciparum drug resistance, as
reported with sulfadoxine/pyrimethamine and with chloroquine
(24, 25, 34). Increasing prevalence of P. falciparum DHFR WT
alleles was observed in Tanzania after the use of insecticide-
treated nets (24). In Zimbabwe, the introduction of indoor re-
sidual insecticide spraying (IRS) was associated with a fourfold
reduction in the odds of chloroquine therapeutic failure (25),
despite years of ongoing drug pressure. Cessation of the IRS was
subsequently linked to a rebound in chloroquine resistance (25).
Given the vector-selective pressure on parasite-resistant alleles
observed in this study, it would be expected that mosquito control
may affect the prevalence of drug resistance, and this link should
be considered in control programs.
It is important to understand specific mechanisms by which the
relative proportions of resistant alleles change between human
and mosquito phases. One possibility might be the disparity in
differentiation to gametocytes reported to occur between WT
and resistant alleles (35). This difference may also relate to the
curious switch in the proportions of S108T and S108N alleles
seen between midgut and salivary gland infections. Drug-re-
sistant alleles are known to be associated with altered biological
fitness of the parasite (36, 37). It is therefore possible that sur-
vival differences under immune clearance within the human and
mosquito phases, and presence or absence of drug selection, may
play significant roles. Analogous differences were observed in
isolation frequencies of Borrelia species from ticks and human
patients from the same endemic region (38).
The P. falciparum polymorphisms found in humans were
expected from selection pressure due to decades of sulfadoxine/
pyrimethamine use. The underlying basis for P. falciparum poly-
morphisms in mosquitoes is not clear. Structural modeling
revealed distinct differences between the pyrimethamine-resistant


























Fig. 2. Prevalence of P. falciparum pyrimethamine- and cycloguanil-re-
sistant DHFR mutants in 796 malaria vector mosquitoes. Spray catches were
obtained. Midguts (A) and salivary gland (B) specimens were separated, and
DNA was PCR amplified and analyzed for allele-specific polymorphisms by
restriction digestion confirming midgut infections (n = 81) and mosquito
gland infections (n = 62). y-axis numerals denote DHFR codons. Represented
are WT, pyrimethamine-resistant mutants (S108N, N51I, C59R, and triple
mutants), cycloguanil-resistant mutants (S108T, A16V, and double mutant),
and mixed alleles (WT+S108T or designated mutant+S108T).
Table 2. Odds for key P. falciparum DHFR resistant polymorphisms in human blood smear-positive samples compared with blood
smear-negative samples and mosquito midguts and salivary glands
Odds ratio (95% CI), human microscopy positives compared with
Allele Mosquito midgut Mosquito salivary gland Human submicroscopic infections
S108N 101 (34.3–299.0); P < 0.001 15 (5.7–39.5); P < 0.001 1 (0.4–3.5); P = 0.753
N51I 32 (11.4–87.6); P < 0.001 29 (10.9–76.5); P < 0.001 1 (0.5–4.3); P = 0.684
C59R 88 (11.6–662.5); P < 0.001 6 (2.5–12.2); P < 0.001 1 (0.4–1.8); P = 0.724
S108N+N51I+C59R triple mutant 18 (1.9–172.2); P < 0.001 5 (1.2–22.7); P < 0.001 2 (0.6–5.8); P = 0.292
S108T —; P < 0.001 —; P < 0.001 —; P = 0.006
A16V —; P < 0.001 —; P = 0.208 —; P = 0.054
S108T+A16V double mutant —; P = 0.948 —; P < 0.001 —; P = 0.054
I164L —; P = 0.081 — —
Mosquito midgut, n = 165; mosquito salivary gland, n = 146; human submicroscopic infections, n = 147. —, Odds ratio could not be calculated due to zero
frequency in human infections.
Table 3. Odds of P. falciparum DHFR resistant polymorphisms in
mosquitoes with a blood meal compared with unfed mosquitoes
Mutant Odds ratio (95% CI) P
S108N 0.985 (0.371–2.616) 0.975
S108T 0.971 (0.379–2.491) 0.952
N51I 1.461 (0.295–7.227) 0.924
C59R 2.824 (0.343–23.255) 0.539
A16V 0.833 (0.274–2.535) 0.748
I164L* — —
Mosquitoes with a blood meal, n = 105; unfed mosquitoes, n = 60.
*Statistics could not be computed because only one sample bore mutant.











and these changes may provide a molecular explanation for the
host specificities. Overall, mutations causing pyrimethamine re-
sistance were all nonconservative substitutions—replacement of
a serine with an asparagine, an asparagine with an isoleucine, or a
cysteine with an arginine. In contrast, mutations causing cyclo-
guanil resistance were very conservative—replacement of a serine
with a threonine or an alanine with a valine.
The Ser-108 residue plays a key role in DHFR catalysis and
protein structure and may explain the contrasting antifolate-re-
sistant polymorphisms reported here. Previous kinetic studies
(39, 40) showed that S108N is a loss-of-function mutant, con-
sistent with reduced fitness in the mosquito vector despite pyri-
methamine-induced selection in humans (Figs. 1 and 2). In
contrast, S108T is a gain-of-function mutant. The specific activity
of S108T is approximately twice that of the WT, whereas Km
values of this mutant for 7,8-dihydrofolate and NADPH are
<25% of the WT (39). These data suggest that the S108T mu-
tation enhances the DHFR activity, possibly conferring an ad-
vantage to the parasite, whereas within the midgut, P. falciparum
parasites carrying this mutation may outgrow WT parasites while
forming oocysts. After rupture of the oocysts, the emerging
sporozoites are nonproliferating. Additionally, because sulfa-
doxine/pyrimethamine has long been used in this region of
Africa, the advantage of S108T parasites may only apply to the
mosquito cycle, and not the human cycle, because pyrimethamine
imposes selective pressure favoring mutations such as S108N. In
this study, S108T accounts for 90% of alleles in mosquito midgut
infections, supporting the above hypothesis. Nevertheless, it does
not explain why S108T prevalence is not elevated in human
infections during absence of sulfadoxine/pyrimethamine selection
pressure. Future studies will be needed to elucidate the candi-
date factors underpinning these allele patterns.
The human populations and mosquitoes surveyed in this study
were all from one rural area in southern Zambia. Before general
significance can be established, it will be essential to undertake
similar surveys in other areas where malaria is endemic. Poly-
morphisms in P. falciparum genes encoding resistance to other
antimalarial drugs should also be examined. If contrasting drug-
resistant phenotypes are confirmed in other regions, it may be
useful to examine both human and vector infections during ep-
idemiological surveillance for antimalarial drug-resistant alleles.
Materials and Methods
See SI Materials and Methods for additional details.
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA Majority
---------+---------+---------+---------+-----
         310       320       330       340
---------+---------+---------+---------+-----
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA 3D7
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA F1  A
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA F2  A
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA F3  A




GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA F19 A 
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA F21 A 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M1  A
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M3  A 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M7  A
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA M9  A 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M10 A 
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA M15 A 
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA M18 A 
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA M19 A 
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA M20 A 
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA M21 A 
GTTGTAGTTATGGGAAGAACAACCTGGGAAAGCATTCCAAAAAAA M23 A 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA F1  H 
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA F2  H 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA F3  H 
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA F4  H 
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA F5  H 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M1  H 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCTTTCCAAAAAAA M2  H 
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M3  H 
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA M4  H
GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA M5  H
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA M6  H
Fig. 3. DNA sequence alignments for P. falciparum DHFR. DNA flanking
nucleotide 323 (amino acid codon 108) obtained from amplicons M3-F/ (M)
and F-M4 (F) from human (H) and Anopheles mosquito (A) samples are
plotted against standard clone 3D7 (GenBank accession no. AL844503; gene
ID 812524). Nucleotide 323 encoding amino acid 108 is accentuated. AGC
encodes WT S108; AAC encodes Pyr-resistant mutant S108N (blue); ACC
encodes Cyc-resistant mutant S108T (yellow). Identical DNA sequences were
obtained from both duplicate amplicons except one mosquito set (F19 A,
M19 A) and one human set (F2 H, M2 H), which contained mixed infections.






























Wild type Pyrimethamine resistance Cycloguanil resistance
A
B
Fig. 4. Key structural variances at
amino acid 108 in WT and resistant
mutants of P. falciparum DHFR. Repre-
sented are crystal structures of WT DHFR
(S108WT) and S108N mutant (PDB ID
codes 1J3I and 3JSU). The structure of the
S108T mutant was derived by molecular
modeling. (A) Note a 2.56-Å hydrogen
bond between the pyrophosphate moi-
ety of NADPH and the hydroxyl group of
the S108 WT or S108T residue; no effec-
tive hydrogen bond exists in the S108N
mutant due to the 5.40-Å distance. (B)
Note extra methyl group in the S108T
mutant forms van der Waals interactions
with a nearby hydrophobic area com-
posed of Met-104, Ile-112, and Ile-164.
The side chains of S108WT, S108T,
S108N, Met-104, Ile-112, Ile-164, and
NADPH are highlighted with sticks and
spheres; the hydrogen bond is shown as
the dashed line with the distance la-
beled, and the protein backbone is
shown in a cartoon model.
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Area and Population. The study was conducted during the 2006–2007 peak
malaria transmission season in 15 representative 25-km2 geographical grids near
Macha in the Southern Province of Zambia. Willing individuals of all ages from
the resident BaTonga communities were eligible to participate in the study.
Study Design and Sample Collection. The study was a prospective cross-sec-
tional design. P. falciparum malaria infections in sympatric contemporane-
ous human and mosquito populations were typed for DHFR-resistant alleles.
DNA Extractions. Mosquito samples were subjected to a simplified Chelex
protocol (41) for P. falciparum DNA extraction. Human blood samples
spotted on filter paper were air-dried, and the Chelex protocol (12) was used
to extract parasite DNA
Assays for Antifolate Drug-Resistant Alleles. P. falciparum was genotyped by
nested PCR and allele-specific restriction enzyme digestion (26) at DHFR
amino acid codons 108, 51, 59, 16, and 164.
A random subset of six samples from human, seven mosquito midgut, and
six mosquito salivary gland infections were subjected to independent se-
quence confirmation of P. falciparum amplicons at the Johns Hopkins DNA
analysis core facility.
Structural Modeling. The structure of S108T DHFR mutant was modeled with
PyMol (www.pymol.org) by using the WT DHFR crystal structure (PDB ID
code 1J3I) as the template. The quadruple DHFR mutant structure (PDB ID
code 3JSU) was used as the S108N mutant.
Data Analysis. Mantel–Haenzel’s χ2 test and multivariate binary logistic
models were used to analyze differences in composition of resistant alleles
among human and mosquito phases. Odds of resistant mutants were de-
termined from the logistic regression models.
Ethics. The study was approved by both the national (University of Zambia)
research ethics committee and the Johns Hopkins institutional review board.
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